[Amrinone in catecholamine refractory heart failure in septic shock]

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Context:

• Septic shock often leads to catecholamine-refractory heart insufficiency.
• Mechanical ventilation with high oxygen concentration and PEEP is common in these patients.
• Existing treatments may not fully address the complex haemodynamic and respiratory issues.

Purpose:

• To evaluate the efficacy of Amrinon, a novel bipyridine-derivate, in treating heart insufficiency in septic shock.
• To assess Amrinon's impact on haemodynamic parameters, pulmonary function, and renal output.
• To determine the survival rate in patients receiving Amrinon therapy.

Summary:

• Amrinon administration (1 mg/kg bolus, then 10 mcg/kg/min infusion) improved haemodynamics in seven septic shock patients.
• Key improvements included reduced tachycardia (>30%), increased blood pressure (25-30%), decreased pulmonary pressures (35-45%), and nearly doubled cardiac output.
• Pulmonary insufficiency and oliguria/anuria also showed improvement during Amrinon therapy (24-36 hours, 800-1440 mg total dose).

Impact:

• Six out of seven patients survived the severe illness.
• Amrinon demonstrated a positive effect on haemodynamic instability and organ function in septic shock.
• Further research may explore Amrinon's role in managing complex critical care scenarios.